|
|
| Sarcoma
Oncology
Trials |
| TITLE |
MSKCC
1705: A Multicenter Phase II study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas |
| DESCRIPTION |
This study will evaluate the effect of sorafenib on sarcoma. Sorafenib is a new type of “targeted” chemotherapy that attacks specific proteins. Patients will receive sorafenib twice a day for four weeks continuously in this study. |
| ELIGIBILITY
|
- Patients must have histologically or cytologically confirmed sarcoma or giant hemangioma except GIST
- Subjects must have metastatic and/or locally advanced or locally recurrent disease.
- 0-1 prior chemotherapy regimens for metastatic disease and no prior treatment with small molecule inhibitors of MAPK signaling intermediates
- Age > 18 years
- ECOG Performance status must be 0 - 2.
- Patients must have normal bone marrow, liver and kidney function
|
| CONTACT |
Anne Ness RN at 216-844-1637 |
|
